Main Conference Day 3Friday, 29 May 2026 - European Time GMT+1

We present Germinal, a model for performing epitope-targeted design of de novo nanobodies and scFvs against a wide range of epitopes, including the ability to design specificity or breadth across multiple targets.

Generative AI is redefining what’s possible in biologics discovery — enabling scientists to explore protein sequence space more efficiently, design higher-performing molecules, and accelerate the path from concept to candidate. At Cradle, we are developing intuitive software tools that allow protein engineers to directly leverage generative AI models within their existing workflows. This presentation will showcase how Cradle’s technology enables scalable and reproducible protein design, combining advanced AI architectures with user-centered design to reduce cycle times and ultimately create better biologics.

We ran an open protein design competition in where 100+ participants from industry and academia submitted binders against Nipah virus. Testing 1000 sequences experimentally in our lab revealed which computational methods translate to experimental success, with hit rates varying 10-fold between approaches. We'll share lessons on benchmarking design pipelines, the value of negative data, and how open competitions can accelerate the field when paired with standardized experimental validation.

Ability Biotherapeutics presents AbiLeap™ – a proprietary AI-enabled platform to systematically generate conditionally active antibodies. Trained on one of the largest therapeutic antibody databases, AbiLeap achieves unprecedented mutational reach (up to 25 amino acid changes) while retaining epitope specificity and therapeutic-ready humanness. Using AbiLeap we have generated leads against 4 targets and are pursuing IND-enabling studies by 2027.